So erreichen Sie das Zentrum
HCP-Zentrum
Als Einrichtung der Tertiärversorgung ist die Charité in der Lage, Behandlungen für ein vielfältiges Krankheitsspektrum anzubieten. Das Krankenhaus umfasst rund 100 verschiedene Kliniken und Abteilungen, die das gesamte Spektrum der modernen Medizin abdecken. Von Allergien und Immunologie bis hin zu Gefäßchirurgie setzen unsere Diagnose- und Behandlungsoptionen einen Maßstab für andere Gesundheitsdienstleister.
Bild: INTERRAILS, CC BY-SA 4.0, über Wikimedia Commons
Kontakt
Charité – Universitätsmedizin Berlin, Germany
Team
Pr Paul Friedemann
Deutschland
Dr Frederike Oertel
Deutschland
Klinische Studien
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Non infectious Uveitis (TOFU)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab As Monotherapy Or In Addition To Baseline Therapy In Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Moderate-To-Severe Thyroid Eye Disease
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Evaluation of the effectiveness of transcorneal electrostimulation in patients with retinitis pigmentosa - a multicenter, prospective, randomized, controlled and double-blind study on behalf of the G-BA
UV Light-mediated Corneal Crosslinking as (Lymph)Angioregressive Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]